Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2017)
19 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 28, 2017
Slide 1: Shareholder Presentation | Annual General Meeting 28th November 2017
For personal use only Shareholder Presentation | Perth, WA Annual General Meeting | 28th November 2017 Global leader in predictive diagnostics & analytical services ASX: PIQ 1 Proteomics International Laboratories Ltd
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 3: PIQ in brief
PIQ in brief For personal use only Specialist MedTech and Life Sciences company focused on the application of proteomics Revenue generating - Est'd 2001 Listed on Australian Stock Exchange 2015 (code: PIQ) Western Australian Exporter of the Year 2016 World’s first company to receive ISO 17025 labora
Slide 4: Corporate overview
Corporate overview For personal use only Capital Structure Shareholders ASX code PIQ Top 20 Shareholders 63.1% Shares on issue 59m Major Shareholders Lipscombe 27.5% Market capitalisation (@ 18c) $10.6m Dunlop/Randolph Res PL 9.2% Listed (@ 20c); raised $3m Apr 2015 XYLO PL 9.0% Placement/SPP (@ 24c
Slide 5: Business model: strategic rationale
Business model: strategic rationale For personal use only Three integrated areas Unifying “Promarker™” platform technology - leverage & efficiency Analytical services Best in class Quality Control testing Biosimilars & biologics Pharmacokinetic (PK) testing for clinical trials Diagnostics Proven tec
Slide 6: Analytical services
Proteomics International For personal use only Analytical services 6 Proteomics International Laboratories Ltd
Slide 7: Accreditation
Accreditation For personal use only World’s first company to receive ISO 17025 laboratory accreditation for proteomics services (2009) All sample analysis is undertaken in accordance with the standards of: • ISO/IEC 17025:2005 (Chemical Testing); and • ISO/IEC 17025:2005 (Research and Development) I
Slide 8: Fast growing biosimilars market
Fast growing biosimilars market For personal use only Analyses required to demonstrate biosimilarity Protein sequence mapping Intact mass determination N/C-terminal sequencing by mass spectrometry N-terminal (Edman) sequencing Amino acid analysis Disulphide mapping Impurity profiling (
Slide 9: Diagnostics & Biomarkers
Proteomics International For personal use only Diagnostics & Biomarkers 9 Proteomics International Laboratories Ltd
Slide 10: Promarker platform technology
Promarker™ platform technology For personal use only Unique protein biomarker Identification of Disease or ‘fingerprints’ Condition 10 Proteomics International Laboratories Ltd
Slide 11: Case study – the PromarkerD success story
Case study – the PromarkerD success story For personal use only The Problem 422 million people globally have diabetes (World Health Organisation) 1 in 3 diabetic adults have chronic kidney disease (US Centre for Disease Control) There are no early symptoms of diabetic kidney disease There is current
Slide 12: PromarkerD – key findings
PromarkerD – key findings For personal use only 12 Proteomics International Laboratories Ltd
Slide 13: PromarkerD versus current tests
PromarkerD versus current tests For personal use only Current 'gold standard' tests (ACR or eGFR) cannot predict kidney decline PromarkerD can correctly predict 86% of the previously kidney disease- free diabetic patients who go on to develop chronic kidney disease up to 4 years in advance Sensitivi
Slide 14: Commercialisation on track
Commercialisation on track For personal use only 1 Patents for DKD were first granted in the USA, Singapore and Australia in 2015, and in China and Russia in 2016; other jurisdictions remain pending. An expansion of the PromarkerD patent to all kidney disease was granted in the USA in August, and in
Slide 15: Pharmacokinetic testing (PK) for clinical trials
Proteomics International For personal use only Pharmacokinetic testing (PK) for clinical trials 15 Proteomics International Laboratories Ltd
Slide 16: Pharmacokinetic testing (PK)
Pharmacokinetic testing (PK) For personal use only Revenues have commenced Pre-clinical and clinical quantitative assays for any investigational drug product – Accurate and precise – Large and small molecules – Leverages a wealth of expertise in building novel assays – High throughput robotics and h
Slide 17: Value proposition: synergies in combining diagnostics and clinical trials
Value proposition: synergies in combining diagnostics and clinical trials For personal use only Australia is a global leader in clinical trials In 2016 there were over 1500 clinical trials run in Australia-NZ Efficient regulatory framework | High quality trial sites | Results accepted globally Compa
Slide 18: Please contact
Please contact For personal use only Richard Lipscombe Managing Director T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com www.proteomicsinternational.com Terry Sweet Chairman E: t.sweet@proteomicsinternational.com Paul Hart Investor Relations, Canary Capital M: +61 421 051 474 | E: phar
Slide 19: For personal use only
For personal use only 19 Proteomics International Laboratories Ltd
Proteomics International Laboratories — Shareholder Meeting (November 2017) on 6ix